Journal of Cystic Fibrosis
Volume 10, Supplement 2 , Pages S75-S78, June 2011

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

  • T. Pressler

      Affiliations

    • Copenhagen University Hospital, 2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author: Tacjana Pressler, Copenhagen University Hospital, Cystic Fibrosis Center, Blegdamsvej 9, 2100 Copenhagen, Denmark. Tel.: +45 3545 1298;fax: +45 3545 6717
  • ,
  • C. Bohmova

      Affiliations

    • University Hospital Motol, Prague, Prague 5, Czech Republic
  • ,
  • S. Conway

      Affiliations

    • St. James' Hospital, LS9 7TF, Leeds, UK
  • ,
  • S. Dumcius

      Affiliations

    • Vilnius University, 08661 Vilnius, Lithuania
  • ,
  • L. Hjelte

      Affiliations

    • Karolinska, Stockholm CF Centre, Huddinge, 14186 Stockholm, Sweden
  • ,
  • N. Høiby

      Affiliations

    • Copenhagen University Hospital, 2100 Copenhagen, Denmark
  • ,
  • H. Kollberg

      Affiliations

    • Uppsala CF Center, 751 85 Uppsala, Sweden
  • ,
  • B. Tümmler

      Affiliations

    • Medizinische Hochschule Hannover, 30625 Hannover, Germany
  • ,
  • V. Vavrova

      Affiliations

    • University Hospital Motol, Prague, Prague 5, Czech Republic

Abstract 

Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.

Keywords:  Cystic fibrosis , Pseudomonas aeruginosa , Chronic infection , Definitions

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1569-1993(11)60011-8

doi:10.1016/S1569-1993(11)60011-8

Journal of Cystic Fibrosis
Volume 10, Supplement 2 , Pages S75-S78, June 2011